Pfizer

Pfizer has submitted data on its bivalent COVID-19 booster shot that specifically targets the latest omicron subvariants. If authorized, the company says the shots could be ready as soon as September.

Despite the nation reaching the grim milestone of 1 million COVID deaths, ODH Director Dr. Bruce Vanderhoff says Ohio is doing "well" compared to previous spikes.

The Food and Drug Administration expanded authorization of Pfizer-BioNTech's COVID vaccine to enable kids ages 5 to 11 who were vaccinated at least five months ago to get a third shot.

The company warned consumers of several tainted lots of Accuretic and two other versions of the drug because of the presence of a nitrosamine above the acceptable daily intake level.

While approval would only be for those populations, an infectious disease specialist from Mount Carmel Medical Group says may be good for everyone.

Pfizer and BioNTech are planning to ask the Food and Drug Administration to authorize a second COVID-19 booster shot for people age 65 and older.

New research out of New York found the protection of the vaccine against infection in kids ages 5 to 11 dropped from 68% to 12%.

The new recommendation for adolescents age 12-17 came hours after a panel of CDC advisers voted in favor of it. The boosters should be given five months after initial immunization.

The move to shorten the Pfizer booster interval comes as the U.S. shatters daily case records. The recommended interval for those who received Moderna or Johnson & Johnson vaccines has not changed.

The authorization comes in the midst of an explosion of COVID-19 cases nationwide driven by the omicron variant — a surge that has brought a spike in pediatric hospitalizations.